Dalotuzumab - CAS 1005389-60-5

Dalotuzumab (MK-0646) is a recombinant humanized IgG1 monoclonal antibody that specifically targets the insulin-like growth factor 1 receptor (IGF-1R) . its mechanism of action involves the inhibition of IGF-mediated oncogenic signaling, which subsequently induces apoptosis and cell cycle arrest in tumor cells, and it has demonstrated enhanced antitumor efficacy when used in combination with other chemotherapeutic agents.

IGF-1R, Apoptosis

Apoptosis, Tyrosine Kinase/Adaptors

1005324

0.993

-20°C

Ice Packs

Inhibitory Antibodies